Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26020597 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Prateek Rai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA. Hauptthemen laut MEDLINE: Paclitaxel, Phosphoric Diester Hydrolases. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Middle Tennessee State University Startup Funding, Wellcome Trust, Middle Tennessee State University.
Abstract (Originalsprache)
The autotaxin–lysophosphatidic acid receptor (ATX-LPAR) signaling axis is pivotal in various clinical conditions, including cancer and autoimmune disorders. This axis promotes tumorigenicity by interacting with the tumor microenvironment, facilitating metastasis, and conceding antitumor immunity, thereby fostering resistance to conventional cancer therapies. Recent studies highlight the promise of ATX/LPAR inhibitors in combination with conventional chemotherapeutic drugs to overcome some forms of this resistance, representing a novel therapeutic strategy. In the current study, we employed structure-based virtual screening, integrating pharmacophore modeling and molecular docking, to identify MolPort-137 as a novel ATX inhibitor with an IC50 value of 1.6 ± 0.2 μM in an autotaxin enzyme inhibition assay. Molecular dynamics simulations and binding free energy calculations elucidated the binding mode of MolPort-137 and its critical amino acid interactions. Remarkably, MolPort-137 exhibited no cytotoxicity as a single agent but enhanced the effectiveness of paclitaxel in 4T1 murine breast carcinoma cells and resensitized taxol-resistant cells to paclitaxel treatment, which highlights its potential in combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
- Department of Chemistry, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
- Department of Chemistry, Shiv Nadar Institution of Eminence, Delhi 201314, India.
- Department of Biology, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
- Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 37132, USA.
ORCID-Profile: Prateek Rai, Gábor J Tigyi, April M Weissmiller, Kshatresh Dutta Dubey, Souvik Banerjee
Förderung
- Middle Tennessee State University Startup Funding
- Wellcome Trust
- Middle Tennessee State University
- MT Internal Grant Opportunities
Zitieren
APA
Rai, P., Clark, C. J., Kardam, V., Womack, C. B., Thammathong, J., Norman, D. D., Tigyi, G. J., Bicker, K., Weissmiller, A. M., Dubey, K. D., & Banerjee, S. (2025). Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020597
Vancouver
Rai P, Clark CJ, Kardam V, Womack CB, Thammathong J, Norman DD, et al. Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020597
BibTeX
@article{Rai2025,
author = {Rai, Prateek and Clark, Christopher J and Kardam, Vandana and Womack, Carl B and Thammathong, Joshua and Norman, Derek D and Tigyi, Gábor J and Bicker, Kevin and Weissmiller, April M and Dubey, Kshatresh Dutta and Banerjee, Souvik},
title = {Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26020597}
}
EUVIMED